| Thomas O. Hecht |
Thomas O. Hecht is the founder of HHC consulting, founded in 2002, and Cell Medica Switzerland AG, founded in 2009. He is currently the Chairman-Supervisory Board at Affimed NV since 2007, Chairman-Supervisory Board at Affimed AG since 2005, Chairman at Orion Biotechnology Canada Ltd. since 2019, Chairman-Supervisory Board at Affimed GmbH since 2007, Chairman at Aelix Therapeutics SL since 2017, Independent Director at BioInvent International AB since 2020, and President & Director at Haemosan, Inc. He previously held positions as Chairman & Chief Executive Officer at Telormedix SA from 2009 to 2011, Executive Chairman at Cytos Biotechnology AG from 2003 to 2012, Chairman at ESBATech, a Novartis Co. GmbH from 2004 to 2009, Chairman at Vaximm AG from 2016 to 2020, Chairman at Lipideon Biotechnology AG, Chairman-Supervisory Board at SuppreMol GmbH from 2008 to 2015, Director at The Caisse de dépôt et placement du Québec, Independent Director at IBEX Technologies, Inc., Director at Société Générale de Financement du Québec, Non-Executive Director at Kuur Therapeutics Ltd. from 2012 to 2020, and Director at Humabs BioMed SA from 2013 to 2017. He also held the position of Co-Head-Bone Marrow Transplantation Program at the University of Freiburg and Vice President-Marketing at Amgen (Europe) GmbH from 1989 to 2002. Hecht holds a doctorate degree from the University of Freiburg, a graduate degree from McGill University, and an undergraduate degree from Sir George Williams University. |
| Denise Mueller |
Ms. Denise Mueller is a Chief Business Officer at Affimed NV and a President at Affimed, Inc. She received her undergraduate degree from Virginia Polytechnic Institute & State University. |
| Wolfgang Fischer |
Wolfgang Fischer is currently the Chief Operating Officer at Affimed NV and Affimed GmbH. He previously worked as the Regional Medical Director-Hematology at Novartis Pharma Schweiz AG. He holds a doctorate degree from the Swiss Federal Institute of Technology and the University of Würzburg Medical School. |
| Leila Alland |
Leila Alland is an Independent Director at Abeona Therapeutics, Inc., a Director at Jubilant Therapeutics, Inc., and a Non-Executive Director at Radiopharm Theranostics Ltd. She previously worked as a Director at Cytovia Therapeutics, Inc., Chief Medical Officer at Affimed NV, Vice President & Head-Oncology at AstraZeneca LP, and Chief Medical Officer at Tarveda Therapeutics, Inc. She also held the position of Assistant Professor-Pediatrics at Albert Einstein College of Medicine, Inc. and Chief Medical Officer at PMV Pharmaceuticals, Inc. Alland received her undergraduate degree from the University of Pennsylvania and her doctorate from New York University School of Medicine. |
| Andreas Harstrick |
Andreas Harstrick is currently the Chief Executive & Medical Officer at Affimed NV. He previously worked as a Director at Lilly Oncology. From 2008 to 2014, he was the Senior Vice President-Medical Sciences at ImClone LLC. He also served as the Chief Medical Officer at Molecular Partners AG from 2015 to 2019. Prior to that, he held the position of SVP-Global Clinical Development Unit Oncology at Merck Serono Ltd. from 1998 to 2008. Dr. Harstrick's education includes a doctorate degree from the University of Hannover in 1986. |
| Harry Welten |
Harry Welten is currently the Chairman at Proteomedix AG, Chairman at Virometix AG, Director at BioSupport AG, Director at Kanyos Bio, Inc., Chief Financial Officer at Affimed NV, Member-Management Board at Horizon Therapeutics Switzerland GmbH, Member-Foundation Council at Fondation De l'Hôpital Barrie Memorial, Member-Foundation Council at HBM Fondation, and Member-Supervisory Board at Affimed GmbH. He previously served as Chairman at Novaremed AG, Director at UBS Securities LLC, Director at Kuros Biosurgery Holding AG, Independent Director at DMS Imaging SA, Director at Synosia Therapeutics, Inc., Director at BiognoSYS AG, Director at Proteomedix AG, Director at Anokion SA, Director at Kuros Biosciences Ltd., Director at Kuros Biosciences AG, and Member-Management Board at Synosia Therapeutics AG. He also held the position of Chief Financial Officer & Executive Vice President at Cytos Biotechnology AG and Chief Financial Officer & Senior Vice President at Arpida AG. Mr. Welten completed his undergraduate and MBA degrees from The Trustees of Columbia University in The City of New York. |
